4Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med, 2007, 356 : 998-1008.
5Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation,2007, 115 : 813-818.
6Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med ,2008, 359 : 1330-1342.
7Seung KB, Park DW, Kim YH, et al. Stents versus coronaryartery bypass grafting for left main coronary artery disease. N Engl J Med,2008, 358 : 1781-1792.
8Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med, 2007, 356: 1020-1029.
9Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in massachusetts. Circulation,2008, 118: 1817-1827.
10Rawles JM.Qualification of the benefit of earlier thrombolytic therapy:five years results of the Grampian region early antistreplase trial(GREAT).J Am Coll Cardiol,1997,30(5):1181-1186
